EyePoint Pharmaceuticals, Inc. (Formerly pSivida Corp.) Extends Closing of Compulsory Sale Facility

WATERTOWN, Mass., 20 July 2018 – EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp. (ASX:PVA)) (NASDAQ:EYPT) ("**the Company**"), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, removed its CHESS Depositary Interests ("**CDIs**") from the Official List of the Australian Securities Exchange ("**ASX**") on 7 May 2018.

Further to the letter sent to CDI holders on 4 April 2018, the Company announces that it will be extending the date on which the Compulsory Sale Facility will close. The following table sets out the revised indicative timeframe for completion of the process related to the Company's delisting from the ASX.

Date*	Event
20 July 2018	**Voluntary Sale Facility closes** Last date to lodge a Sale Instruction Form to participate in the Voluntary Sale Facility. Last date to lodge an off-market transfer for CDIs.
23 July 2018	**Compulsory Sale Facility opens** Process of automatic sale of underlying Common Stock of any remaining CDIs begins.
16 November 2018	**Compulsory Sale Facility closes** Date by which all underlying Common Stock represented by any remaining CDI holders will be sold under the Compulsory Sale Facility. The proceeds of sale will be converted to Australian dollars (less costs and any applicable taxes) and remitted to the CDI holders.

* All dates and times in this letter are references to the date and time in Sydney, Australia, unless otherwise expressly stated, and are indicative only. The Company reserves the right to change or extend any of the dates and times in this letter and will promptly announce any such change on its website http://investors.psivida.com/index.cfm.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) (www.eyepointpharma.com), headquartered in Watertown, MA, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. In addition, DEXYCU™ was approved by the FDA on February 9, 2018. DEXYCU, administered as a single intraocular dose at the end of ocular surgery for the treatment of postoperative inflammation, is the first and only FDA-approved intraocular product with this indication. DEXYCU employs the Verisome™ extended-release drug delivery technology, which encompasses a broad number of related but distinct drug delivery systems capable of incorporating an extensive range of active agents, including small molecules, proteins and monoclonal antibodies. ILUVIEN® (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema, licensed to Alimera Sciences, Inc., is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant), for posterior uveitis, is licensed to and sold by Bausch & Lomb, Inc. The New Drug Application (NDA) for EyePoint's lead product candidate, YUTIQ™ three-year treatment of non-infectious uveitis

affecting the posterior segment of the eye, has been accepted for filing by the FDA and is currently under standard review with a Prescription Drug User Fee Act (PDUFA) date of November 5, 2018. The Company's pre-clinical development program is focused on using its core Durasert™ and the Verisome™ platform technologies to deliver drugs to treat wet age-related macular degeneration, glaucoma, and other diseases. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter, LinkedIn, Facebook and Google+.

Contact:

Argot Partners
Kimberly Minarovich
(646) 368-8014
kimberly@argotpartners.com

Joseph Rayne
(617) 340-6075
joseph@argotpartners.com